Table 1 Patient demographics and key clinical features

Median age at LMD diagnosis (range)

Male

Site of primary melanoma

Cutaneous

Primary CNS

Uveal

Acral lentiginous

Mucosal

Unknown

Melanoma mutation

BRAF V600E

BRAF V600K

GNA11/GNAQ

NRAS

Other

Unknown (not sufficient tissue for sequencing)

ECOG performance status

0

1

2

LDH elevated above institutional limit

CSF positive for malignant cells at baseline

MRI brain findings consistent with LMD at baseline (MRI spine with no evidence of LMD)

MRI spine findings consistent with LMD at baseline (MRI brain with no evidence of LMD)

Both MRI brain and spine consistent with LMD at baseline

Parenchymal brain metastases before LMD diagnosis

Extracranial disease present at time of LMD diagnosis

Prior therapies to LMD diagnosis

Systemic therapy

Checkpoint inhibitors

BRAF, MEK or BRAF/MEK inhibitors

(Bio)Chemotherapy

Other^a

Median number of previous metastatic melanoma directed therapies (range)

Radiation to brain or spine

Whole-brain radiotherapy

Stereotactic radiation

LMD directed systemic therapies before IT/IV nivolumab

Checkpoint inhibitors

BRAF, MEK or BRAF/MEK inhibitors

Chemotherapy

Intrathecal therapy with IL-2

On dexamethasone/corticosteroids at enrollment

Dexamethasone (or equivalent) dose, median (mg d⁻¹)^b

On concurrent BRAF/MEK therapy